Codrug

Codrug

Retinal Drug Delivery

Published in Glenn J. Jaffe, Paul Ashton, P. Andrew Pearson, Intraocular Drug Delivery, 2006

Another approach has been the use of codrug implants. In this case, the codrugs used formed an insoluble conjugate. Parent drugs were released as the conjugate dissolves and hydrolyzed in the vitreous. In this system, the release rate can be adjusted to give either first- or zero-order release and enables either simultaneous or asynchronous release of the two drugs. Another advantage is that no polymer is necessary to control release. Jaffe and coworkers reported that a codrug pellet providing constant, equimolar release of 5-FU and triamcinolone was effective in the prevention of PVR in a rabbit model (144). They subsequently found that a more advanced codrug that provided release of 5-FU over approximately two weeks, and a longer release of fluocinolone acetonide was even more effective (145). A more detailed discussion of drug delivery and PVR is provided in a later chapter.

Co-drug of isoniazid and sulfur containing antioxidant for attenuation of hepatotoxicity and treatment of tuberculosis

View Article

Journal Information

Published in Drug and Chemical Toxicology, 2022

Neha V. Bhilare, Suneela S. Dhaneshwar, Kakasaheb R. Mahadik, Arunava Dasgupta

Inspired from this rationale, we propose hepatoprotective and antimycobacterial co-drug in which INH is covalently linked via an amide bond to LA. We hypothesize that INH can be transiently disguised at the N2 center of hydrazinic chain in order to obstruct NAT-induced acetylation and CYP2E1 triggered oxidation. Specifically, this work includes synthesis of novel codrug, the study of its release kinetics, and bioevaluation of its hepatoprotective and antimycobacterial potential.

Explore chapters and articles related to this topic

Retinal Drug Delivery

Co-drug of isoniazid and sulfur containing antioxidant for attenuation of hepatotoxicity and treatment of tuberculosis